Tech Company Financing Transactions

aTyr Pharma Funding Round

On 10/26/2010, aTyr Pharma raised $23 million in Series C funding from Domain Associates, Alta Partners and Cardinal Partners.

Transaction Overview

Company Name
aTyr Pharma
Announced On
10/26/2010
Transaction Type
Venture Equity
Amount
$23,000,000
Round
Series C
Investors

Domain Associates (Lead Investor) (James Blair)

Alta Partners (David Mack)

Cardinal Partners (John Clarke)

Polaris Partners (Amir Nashat)

Proceeds Purpose
Proceeds will be used to accelerate the development of aTyr's preclinical pipeline and advance physiocrine drug candidates into clinical trials.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
3545 John Hopkins Ct. 250
San Diego, CA 92121
USA
Phone
(858) 731-8389
Website
www.atyrpharma.com
Email Address
[email protected]
Overview
aTyr is leveraging Physiocrine biology, a new and important area of human health, to develop first-in-class medicines to treat patients suffering from severe, rare diseases with significant unmet medical need.
Profile
aTyr Pharma LinkedIn Company Profile
Social Media
aTyr Pharma Company Twitter Account
Company News
aTyr Pharma News
Facebook
aTyr Pharma on Facebook
YouTube
aTyr Pharma on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Sanjay Shukla
  Sanjay Shukla LinkedIn Profile  Sanjay Shukla Twitter Account  Sanjay Shukla News  Sanjay Shukla on Facebook
Chief Financial Officer
Jill Broadfoot
  Jill Broadfoot LinkedIn Profile  Jill Broadfoot Twitter Account  Jill Broadfoot News  Jill Broadfoot on Facebook
VP - General Counsel
Nancy Krueger
  Nancy Krueger LinkedIn Profile  Nancy Krueger Twitter Account  Nancy Krueger News  Nancy Krueger on Facebook
VP - Human Resources
Holly Winter
  Holly Winter LinkedIn Profile  Holly Winter Twitter Account  Holly Winter News  Holly Winter on Facebook
VP - Manufacturing
Andrea Cubitt
  Andrea Cubitt LinkedIn Profile  Andrea Cubitt Twitter Account  Andrea Cubitt News  Andrea Cubitt on Facebook

 

 

Browse more venture capital transactions:

Prev: 10/26/2010: RapLeaf venture capital transaction
Next: 10/26/2010: nContact Surgical venture capital transaction

 

Share this article

 

Where The Data Comes From

Our team works diligently to report on tech company VC transactions. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.